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Background: It is said that the chronic outcomes of the two-stent technique for bifurcation
lesions are inferior to that of cross-over single stenting. However, there are many cases where
true bifurcations are difﬁcult to treat by single stenting and, in particular, strategies for bifur-
cation lesions that are not left main trunk (LMT) bifurcations are still not clear.
Objective: This study aims to compare the usefulness of crush stenting with that of cross-over
single stenting using the sirolimus-eluting stent (SES) on bifurcation lesions with the exclusion
of LMT bifurcations.
Methods: Subjects were 92 consecutive patients (100 lesions) who underwent cross-over single
stenting or crush stenting using SES for bifurcation lesions with the exclusion of LMT bifurcations.
The patients were divided into 33 patients with 34 lesions, in whom the stent was implanted
in the main vessel alone with the kissing balloon technique performed for the main vessel and
side branch (Single-stenting group; S group), and 59 patients with 66 lesions, in whom the stent
was implanted through crush stenting (Crush-stenting group; C group). The two groups were
compared for target lesion revascularization (TLR) and major adverse cardiac events (MACE).
Results: There were no differences for TLR, with this conducted in the main vessel in 5.9%
of S group and 4.5% of C group. There was no difference between the groups in MACE
with 9.1% in S group and 8.5% in C group. No signiﬁcant difference was seen in MACE-free
survival rate in the chronic phase with 93.9% for S group and 94.9% for C group (P =NS).
∗ Corresponding author. Tel.: +81 3 5493 2989; fax: +81 3 5493 2989.
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Conclusion: No differences in chronic clinical outcomes were revealed in a comparison between



































Quantitative coronary angiography (QCA) measurements
were obtained through CCIP 310 (Cathex Co. Ltd., Tokyo,
Japan), measuring RD, lesion length, and minimum lumencross-over single stenting and
© 2009 Japanese College of C
Introduction
In the era of the bare metal stent (BMS), treatment of
bifurcation lesions posed problems such as low angiographic
success and a high rate of side branch restenosis, making
bifurcation lesions one type of lesion difﬁcult to treat [1].
In particular, for lesions with a stenosis in the ostium of the
side branch, side branch occlusion often occurred through
a plaque shift during stent implantation in the main vessel,
and it was reported that this could lead to in-hospital major
adverse cardiac events (MACE) [2]. By inhibiting neointi-
mal formation, the drug-eluting stent (DES) clearly showed
less late loss than BMS [3]. Taking advantage of this char-
acteristic, recent years have seen a variety of two-stent
strategies (crush stenting [4], Y-stenting [5], T-stenting [6],
and culotte stenting [7]) performed for the stenting of both
the main vessel and side branch in true bifurcations. It has
been reported that this prevents occlusion of the side branch
and, compared to BMS, reduces restenosis in bifurcation
lesions as well as the onset of late MACE [8]. But proce-
dures currently performed by two-stent strategy still reveal
a high percentage of side branch restenosis at about 20%
[8—10] and it has been reported that compared to cross-
over single stenting, there is also a higher incidence of stent
thrombosis (ST) [8]. Notably, for left main trunk (LMT) bifur-
cation lesions, it became clear that the chronic outcomes of
a two-stent strategy were inferior to that of cross-over sin-
gle stenting, and it has been recommended as a general rule
to perform cross-over single stenting in bifurcation lesions
[11]. However, although there are many cases of high-risk
true bifurcations that are difﬁcult to treat by single stenting,
strategies for bifurcation lesions that are not LMT lesions are
still not clear.
Among the various two-stent strategies performed, it is
highly possible that crush stenting proposed by Colombo et
al. [4] in 2002 can fully cover both the main vessel and
side branch regardless of bifurcation angle, and could thus
be a strategy that can remove the gap between stents,
which could occur through other strategies. Problems arose,
however, in this stenting procedure, with a high rate of
restenosis of the side branch ostium and the occurrence of
ST in the chronic phase. In contrast, it has been reported in
recent years that good outcomes are achieved by perform-
ing the kissing balloon technique (KBT) before the end of the
procedure [12]. In addition, the incidence of ST reported in
the outcomes of 2-year follow-up in the j-Cypher trial [13]
was 0.63%, a much lower percentage than that of western
countries. It is possible that the clinical outcomes of crush
stenting on bifurcation lesions in Japanese patients do not
necessarily match those reported in the West.In this current study, we used the sirolimus-eluting stent
(SES) to perform either cross-over single stenting or crush
stenting in non-LMT lesions, and studied the usefulness
of crush stenting in bifurcation lesions by comparing the
chronic clinical outcomes of the two procedures.
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ubjects and methods
ubjects
ubjects were 92 consecutive patients (100 lesions) who
nderwent cross-over single stenting or crush stenting using
ES for bifurcation lesions with the exclusion of LMT bifur-
ations at our institution from June 2004 to May 2008, and
hose clinical progress was able to be followed for 6 months
r more after the procedure. The patients were divided
nto 33 patients with 34 lesions, on whom the stent was
mplanted in the main vessel alone with the KBT performed
or the main vessel and side branch (Single-stenting group;
group), and the 59 patients, 66 lesions, on whom stents
ere implanted in both the main vessel and side branch
hrough crush stenting (Crush-stenting group; C group). The
roups were compared for target lesion revascularization
TLR), ST, MACE including cardiac death, acute myocar-
ial infarction (AMI), TLR, coronary artery bypass grafting
CABG) in the chronic phase (760± 242 days). Subjects who
id not fulﬁll all the following conditions were excluded:
1) a stenosis with a percent diameter stenosis (%DS) of 50%
r more revealed in the main vessel or side branch near
he bifurcation irrespective of morphology or bifurcation
ngle; (2) main vessel reference diameter (RD) of 2.5mm
r larger; (3) side branch RD of 2.0mm or larger, with per-
usion of the side branch believed to be clinically valuable;
4) treatment of both vessels judged necessary from angio-
raphic ﬁndings irrespective of the presence of stenosis 50%
r more in the ostium of the side branch. LMT lesions and
estenosed lesions were also excluded. Bifurcation lesions
ere classiﬁed according to the Medina classiﬁcation [14]
Fig. 1).igure 1 Bifurcation lesions were classiﬁed according to the
edina classiﬁcation [14].































































Age (years) 66.9± 12.3 67.9± 11.7 n.s.
Male/female 28/5 50/9 n.s.
Diabetes mellitus (%) 15 (45.5) 30 (50.8) n.s.
Hypertension (%) 16 (48.5) 28 (47.6) n.s.
Hyperlipidemia (%) 21 (63.6) 32 (54.2) n.s.
Smoking (%) 4 (12.1) 5 (8.5) n.s.
Prior CABG (%) 2 (6.0) 4 (6.8) n.s.
Hemodialysis (%) 2 (6.0) 3 (5.1) n.s.
Diagnosis (%)
SAP 18 (54.5) 31 (52.5)
UAP 2 (6.1) 5 (8.5)
AMI 0 (0) 2 (3.4) n.s.
RMI 3 (9.1) 5 (8.5)
OMI 10 (30.3) 16 (27.1)
Extent of CAD (%)
1-Vessel disease 5 (15.1) 15 (25.3)
2-Vessel disease 16 (48.5) 28 (47.6) n.s.
3-Vessel disease 11 (36.4) 16 (27.1)
Ejection fraction (%) 58.5 61.1 n.s.






















iameter (MLD) before and after the procedure and at late
ollow-up angiography. Angiographic success was deﬁned as
residual stenosis of 20% or less in the main vessel and side
ranch, and thrombolysis in myocardial infarction (TIMI) III
ow. Clinical success was deﬁned as angiographic success
chieved in the main vessel and no in-hospital MACE.
ngioplasty procedure
ll patients were administered 100mg of aspirin before the
rocedure along with 200mg ticlopidine or 50—75mg clopi-
ogrel. Heparin 5000 U was also given before the procedure
nd maintained with the goal of keeping activated clotting
ime at 250—300 s. Dual antiplatelet therapy was contin-
ed after the procedure to the extent possible. Only the
ypherTM sirolimus-eluting coronary stent (Cordis, Johnson
Johnson, Miami, FL, USA) was used in this study.
In the S group, pre-dilatation was performed in the main
essel alone, or on both the main vessel and the side branch,
ollowed by stenting of the main vessel. KBT was performed
n all the cases after re-crossing the guide wire to the side
ranch. In the C group, after pre-dilatation of the main ves-
el and the side branch, the side branch stent was positioned
or full cover of the side branch ostium, and before expan-
ion, the main vessel stent was also positioned to cover
he lesions. Modiﬁed crush stenting was mainly performed
hen a 6 Fr guiding catheter was used, with the balloon
ositioned in the main vessel so that it could crush the
roximal end of the side branch stent. First, after expan-
ion of the stent in the side branch, the system balloon
nd guide wire were retrieved, and following this, the pre-
ositioned stent or balloon was used to crush the part of
he stent protruding into the main vessel. In modiﬁed crush
tenting, this was followed by implantation of a stent in the
ain vessel. The guidewire was re-crossed to the side branch
hrough the struts of the two stents covering the ostium of
he side branch. A balloon was passed to the side branch
nd inﬂated at high pressure (12—16 atm) ﬁrst in the side
ranch alone. KBT was then performed whenever possible.
nﬂation pressure for KBT was about 8 atm. Intravascular
ltrasound (IVUS; Eagle-eye, Volcano Inc., Rancho Cordova,
A, USA) studies were conducted before and after the proce-
ure in both groups if the IVUS catheter was able to cross the
esion. In principle, post-procedural study was conducted
n the main vessel alone, with minimum stent area (MSA)
easured. Additional ballooning of the main vessel was per-
ormed when underexpansion or malaposition was revealed,
r when it was revealed that KBT caused deformation of the
arina in the main vessel.
linical deﬁnition and follow-up
ollow-up of clinical progress was conducted through out-
atient examinations, and late follow-up angiography was
onducted at about 6—12 months after the procedure.
ACEs were compared between the two groups conductedn-hospital and at the chronic phase (760± 242 days).
he MACE-free survival rate was obtained through the
aplan—Meier method and the two groups were compared.
estenosis in late follow-up angiography was deﬁned as a




itoris; UAP, unstable angina pectoris; AMI, acute myocardial
infarction; RMI, recent myocardial infarction; OMI, old myocar-
dial infarction; and CAD, coronary artery disease.
istal and proximal to the stent edge. In addition, TLR was
eﬁned as treatment conducted again on either the main
essel or the side branch in the presence of a stenosis with
DS of 50% or more. Using the ARC* [15] classiﬁcation, ST
as deﬁned as fulﬁlling either the classiﬁcation of deﬁnite
r probable. Its rate of incidence was studied at each of
hese periods up to the chronic phase.
tatistical analysis
ontinuous variables were expressed as mean
alue± standard deviation. The Fisher’s exact test or
he 2 test was used for the association between two
ominal variables, and the unpaired Student’s t test was
sed in the comparison of two independent groups. In
ddition, the rate of MACE-free survival in the chronic
hase was assessed by the Kaplan—Meier method and the
og-rank test was used for analysis. All statistical results
ere determined to be signiﬁcant when P < 0.05.
esults
atient and lesion characteristics
able 1 shows patient characteristics. No signiﬁcant differ-
nce was revealed between the two groups for age, gender,
r clinical background. Table 2 shows lesion characteristics.
A signiﬁcantly larger number of true bifurcation
esions according to the Medina classiﬁcation [Type
,1,1/1,0,1/0,1,1 was revealed in C group, with 16 (47.0%)
n S group and 59 (89.3%) in C group (P < 0.05)]. There was no
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RCA-AV/PD 6 (17.6) 8 (12.1)
LAD-diagonal/HL 18 (53.0) 46 (69.8)
LCx-OM 9 (26.5) 11 (16.6) n.s.
SVG 1 (2.9) 1 (1.5)
Angulation (%)
Y type (<70◦) 24 (70.4) 46 (69.7)
T type (>70◦) 10 (29.6) 20 (30.3) n.s.
Bifurcation type (%)/medina classiﬁcation
Type 1,1,1 7 (20.6) 27 (40.9)
Type 1,1,0 5 (14.7) 1 (1.5)
Type 1,0,1 4 (11.8) 13 (19.6)
Type 0,1,1 5 (14.7) 16 (24.5) n.s.
Type 1,0,0 5 (14.7) 3 (4.5)
Type 0,1,0 8 (23.5) 3 (4.5)
Type 0,0,1 0 (0) 3 (4.5)
True bifurcation (%) 16 (47.0) 59 (89.3) <0.05
CTO lesion (%)
Main vessel 2 (5.9) 3 (4.5) n.s.
Side branch 0 (0) 0 (0) n.s.
Calciﬁed (%)
Main vessel 5 (14.7) 15 (22.7) n.s.
Side branch 4 (11.8) 15 (22.7) n.s.
RCA, right coronary artery; AV, atrioventricular coronary artery;
PD, posterior descending coronary artery; LAD, left anterior








RD (mm) 2.95± 0.42 3.04± 0.46 n.s.
Lesion length (mm) 25.5± 8.5 24.1± 9.2 n.s.
MLD (mm) 0.76± 0.34 0.82± 0.32 n.s.
%DS (%) 73.4± 10.3 73.2± 9.7 n.s.
Pre-TIMI grade 3 30 (88.2) 54 (81.8) n.s.
Side branch
RD (mm) 2.32± 0.48 2.46± 0.40 <0.05
Lesion length (mm) 5.4± 3.6 11.3± 5.5 <0.05
MLD (mm) 1.42± 0.66 0.81± 0.44 <0.05
%DS (%) 41.0± 27.7 66.8± 28.9 <0.05



















pdescending coronary artery; HL, high lateral branch; LCx, left
circumﬂex artery; SVG, saphenous vein graft; and CTO, chronic
total occlusion.
signiﬁcant difference between the two groups for calciﬁed
lesions or bifurcation angle.
Baseline angiographic and procedural
characteristics
The guiding catheter used was mainly 6 Fr in the S group
(S group 85.3%; C group 30.3%) and 7 Fr in the C group (S
group 14.7%; C group 69.7%; Table 3). Comparison of pre-
procedural QCA ﬁndings revealed that while main vessel
RD in the C group was not signiﬁcantly different from that







Radial artery 29 (85.3) 62 (93.9)
Brachial artery 4 (11.8) 4 (6.1) n.s.
Femoral artery 1 (2.9) 0 (0)
Guiding catheter size (%)
6 Fr 29 (85.3) 20 (30.3) <0.05
















bRD, reference diameter; MLD, minimum lumen diameter; %DS, %
diameter stenosis; and TIMI, thrombolysis in myocardial infarc-
tion.
n the S group, side branch RD was signiﬁcantly larger in
he C group compared to the S group (S group vs. C group:
ain vessel 2.95± 0.42mm vs. 3.04± 0.46mm, P =NS; side
ranch 2.32± 0.48mm vs. 2.46± 0.40mm, P < 0.05). In addi-
ion, although there was no difference between the two
roups in main vessel lesion length, side branch lesion length
as signiﬁcantly longer in the C group (5.4± 3.6mm vs.
1.3± 5.5mm, P < 0.05). Moreover, although there was no
igniﬁcant difference between the groups in %DS in the main
essel, it was signiﬁcantly greater in the side branch of the
group (41.0± 27.7% vs. 66.8± 28.9%, P < 0.05; Table 4).
No signiﬁcant difference was revealed between the
roups for stent diameter in the main vessel. KBT was per-
ormed in 34 lesions (100%) of the S group and 64 lesions
97.0%) of the C group, but no signiﬁcant difference was
hown (P =NS). KBT balloon size used was signiﬁcantly larger
n the side branch of the C group (2.25± 0.32mm vs.
.54± 0.44mm, P < 0.05; Table 5).
IVUS was performed in 26 patients (76.5%) in the S
roup and 45 patients (68.2%) in the C group (P =NS). From
ost-procedural IVUS ﬁndings, additional ballooning was
erformed in the main vessel alone in 9 lesions (26.4%) of
he S group and 9 lesions (13.6%) of the C group. Main ves-
el MSA after additional ballooning was 6.28± 1.12mm2 in
he S group and 6.58± 1.33mm2 in the C group, showing no
igniﬁcant difference (P =NS; Fig. 2).
ngiographic results and in-hospital outcomes
o signiﬁcant difference was revealed between the two
roups in post-MLD in the main vessel, but this was signif-
cantly larger in the side branch of the C group (S group
s. C group: main vessel 2.89± 0.56mm vs. 2.95± 0.49mm,
=NS; side branch 1.95± 0.42mm vs. 2.38± 0.45mm,
< 0.05). Post %DS was signiﬁcantly greater in the side
ranch of the S group (18.2± 15.5% vs. 2.1± 14.8%, P < 0.05;
able 6). There was no signiﬁcant difference revealed for
ngiographic success in the main vessel, but in the side
ranch this was 79.4% in the S group and 92.4% in the
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Table 5 Procedural characteristics.
Group S, n = 34 Group C, n = 66 P-value
Main vessel
Stent size (mm) 2.92± 0.48 3.03± 0.40 n.s.
Stent length (mm) 26.1± 10.3 26.9± 9.9 n.s.
Final balloon size (mm) 2.96± 0.44 2.99± 0.42 n.s.
Maximal inﬂation pressure (atm) 17.2± 2.6 17.0± 2.2 n.s.
Side branch
Stent size (mm) — 2.62± 0.24
Balloon size (mm) 2.26± 0.42 —
Stent/balloon length (mm) 17.0± 5.2 21.4± 8.2 <0.05
Final balloon size (mm) 2.26± 0.42 2.50± 0.33 <0.05
Maximal inﬂation pressure (atm) 9.7± 2.6 15.7± 2.0 <0.05
Kissing balloon post-stent implantation (%) 34 (100) 64 (97.0) n.s.
KBT balloon size (mm)
Main vessel 2.98± 0.49 2.96± 0.43 n.s.
Side branch 2.25± 0.32 2.54± 0.44 <0.05
KBT inﬂation pressure (atm) 8.5± 1.2 8.4± 1.2 n.s.











oAdditional ballooning for main branch (%) 9
Additional balloon inﬂation pressure (atm) 16
KBT, kissing balloon technique; and IVUS, intravascular ultrasound
group, with a signiﬁcantly higher rate in the C group
P < 0.05). No signiﬁcant difference was revealed between
he two groups in clinical success with 100% in the S group
nd 98.4% in the C group (P =NS). In the S group, 7 patients
ere not able to achieve a residual stenosis of 20% or less





Table 6 Angiographic result and in-hospital outcomes.
Group S, n = 34
Main vessel
RD (mm) 2.93± 0.51
MLD (mm) 2.89± 0.56
%DS (%) 2.5± 7.2
Acute gain (mm) 1.89± 0.78
Pre-TIMI grade 3 34 (100)
Side branch
RD (mm) 2.37± 0.41
MLD (mm) 1.95± 0.42
%DS (%) 18.2± 15.5
Acute gain (mm) 0.61± 0.58
Pre-TIMI grade 3 34 (100)
Angiographic success (%)
Main vessel 34 (100)
Side branch 25 (79.4)
Clinical success (%) 100
In-hospital MACE (%)
Cardiac death 0 (0)
AMI 0 (0)
CABG 0 (0)
RD, reference diameter; MLD, minimum lumen diameter; %DS, % diam
myocardial infarction; and CABG, coronary artery bypass grafting.) 9 (13.6) n.s.
2.5 16.7± 2.4 n.s.
atients were not able to achieve a residual stenosis of 20%
r less in the side branch after the procedure. In addition,
ide branch occlusion after crush stenting was seen in 2
atients: 1 patient was TIMI 0 and the other was TIMI I, and
o improvement was revealed in ﬁnal angiography as well.
here was only 1 case of in-hospital MACE, with onset of

















eter stenosis; MACE, major adverse cardiac event; AMI, acute
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rtwo groups were compared for minimum stent area in the mai
(MSA) signiﬁcantly increased in both groups following dilatation,
the groups for MSA before and after additional ballooning. C gr
AMI in 1 patient in the C group due to side branch occlusion
during the procedure.
Follow-up results
Late follow-up angiography was conducted at 8.1± 3.7
months after the procedure in the S group and at 8.0± 4.3
months in the C group. Although no signiﬁcant difference
was revealed between the two groups in MLD or %DS in
the chronic phase, late loss in the side branch was signif-










RD (mm) 2.95± 0.5
MLD (mm) 2.80± 0.4
%DS (%) 11.3± 10.
Late loss (mm) 0.09± 0.4
Restenosis (%) 2 (5.9)
Target lesion revascularization (%) 2 (5.9)
Side branch
n 25
RD (mm) 2.29± 0.3
MLD (mm) 1.63± 0.3
%DS (%) 30.6± 18.
Late loss (mm) 0.26± 0.4
Restenosis (%) 5 (20.0)
Target lesion revascularization (%) 1 (4.0)
RD, reference diameter; MLD, minimum lumen diameter; and %DS, % dsel before and after additional ballooning. Minimal stent area
no signiﬁcant difference was revealed in a comparison between
Crush-stenting group; S group, Single-stenting group.
s. 0.11± 0.40mm, P =NS; side branch 0.26± 0.41mm vs.
.56± 0.62mm, P < 0.05). Main vessel restenosis occurred
n 2 cases (5.9%) in the S group and 3 (4.5%) in the C
roup (P =NS), and side branch restenosis occurred in 5 cases
20.0%) in the S group and 8 (13.1%) in the C group, with no
ifference between the groups (P =NS). No difference was
evealed for TLR of the main vessel, with 2 (5.9%) in the S
roup and 3 (4.5%) in the C group, and no signiﬁcant differ-
nce was seen for the side branch as well with 1 (4.0%) in the
group and 2 (3.3%) in the C group (Table 7). There was no
ifference between the groups for MACE in the chronic phase
mean follow-up period of 760± 240 days), with 9.1% in the S
Group C P-value
66
5 2.96± 0.41 n.s.
5 2.90± 0.38 n.s.
2 13.8± 9,8 n.s.




7 2.38± 0.35 n.s.
6 1.76± 0.34 n.s.
2 27.3± 21.7 n.s.
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Table 8 Follow-up clinical results.
Group S, n = 33 Group C, n = 59 P-value
MACE (%)
Cardiac death 1 (3.0) 1 (1.6) n.s.
AMI 0 (0) 1 (1.6) n.s.
CABG 0 (0) 1 (1.6) n.s.
Target lesion revascularization 2 (6.1) 2 (3.3) n.s.
Stent thrombosis (%) 0 (0) 2 (3.3) n.s.











































cigure 3 Major adverse cardiac events (MACE)-free survival
aplan—Meier method. No signiﬁcant difference was revealed b
roup and 8.5% in the C group (Table 8). There was no signiﬁ-
ant difference in MACE-free survival rate, with 93.9% in the
group and 94.9% in the C group (P =NS; Fig. 3). ST occurred
n 2 cases in the C group. One was 13 months and the other
as 20 months after the procedure. One patient had self-
iscontinued antiplatelet medication at an early period.
iscussion
s DES clearly reduce restenosis compared to BMS, they
re currently being used in the treatment of various types
f lesions. Among these, however, treatment of bifurcation
esions is one of the issues that remain to be resolved.
In this study, two strategies, crush stenting and cross-
ver single stenting for bifurcation lesions were compared
sing SES, but no difference was revealed between the two
roups in chronic outcomes.
estenosis and TLRn this current study, no signiﬁcant difference was revealed
etween the two groups for restenosis of the main ves-
el, and similarly for the side branch. In the era of the
MS, Yamashita et al. [16] studied the chronic outcomes of





ein the chronic phase (760± 242 days) was compared by the
en the two groups.
ere treated by two-stent strategy (T-stenting, Y-stenting,
-stenting, and culotte stenting) or cross-over single stent-
ng. They reported that main vessel restenosis was 23.1% in
he single-stent group and 45.4% in the two-stent group, and
ide branch restenosis was 20.5% and 37.7%, respectively.
n the other hand, in the same single-institution study,
sing DES, Colombo et al. [4] similarly compared the chronic
utcomes of two-stent strategy (T-stenting, modiﬁed T-
tenting, V-stenting, and culotte stenting) and cross-over
ingle stenting for bifurcation lesions. It was reported that
ain vessel restenosis was 4.8% in the single-stent group and
.7% in the two-stent group, and side branch restenosis was
4.2% and 21.8%, respectively. In this way, two-stent strat-
gy for treatment of bifurcations using DES, as opposed to
MS, not only dramatically reduces the rate of main ves-
el restenosis, but could also improve restenosis of the side
ranch. However, even with DES implantation, two-stent
trategy was not able to surpass the results of the single-
tent group in improving the rate of side branch restenosis.
s a cause of this, it was suggested that the frequent difﬁ-
ulties encountered in fully covering the lesion in the side
ranch ostium by T-stenting could lead to restenosis [4].
xpectations were held that crush stenting, a method that
ould fully cover the lesion at the side branch ostium, would
urther improve the rate of side branch restenosis. How-
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the importance of KBT was unknown, side branch restenosis
was 30%, remaining at a high rate similar to that of other
two-stent strategies [17]. In recent years, the importance
of ﬁnal KBT has become clear, and recently Hoye et al. [18]
reported good outcomes in the group undergoing KBT, with
restenosis of 6.4% in the main vessel and 9.6% in the side
branch. Ge et al. [12] similarly reported that the resteno-
sis rate was 13.8% in the main vessel and 8.6% in the side
branch in the group undergoing KBT, and stated that the side
branch restenosis rate is inﬂuenced by whether or not KBT
is performed. In our study, 97% of the Crush-stenting group
was able to undergo KBT, and their chronic outcomes support
the results of Ge et al. However, for patients who were able
to undergo IVUS studies after KBT was performed, under-
expansion of the stent in the main vessel was revealed in
26.4% of the S group and 13.6% of the C group. In the SIRIUS
trial, Sonoda et al. [19] proposes a MSA >5.0mm2 as the end
point in DES implantation. Although decisions were not made
by measuring MSA in our study, the MSA of those undergoing
additional ballooning consequently improved from 4.77mm2
in the S group and 4.83mm2 in the C group before additional
ballooning to become 6.28mm2 and 6.58mm2, respectively,
after additional ballooning. In the C group, there were cases
of the carina displaced to the side of the main vessel after
KBT, and notably, this was revealed more frequently in cases
where the main vessel and side branch balloons used in KBT
were the same or nearly the same in size. Thus it was sug-
gested that performing KBT, using IVUS for evaluation of
the main vessel in particular, and performing high pressure
ballooning when underexpansion is revealed could further
reduce the incidence of late MACE including TLR.
MACE
In this study, MACE-free survival rate did not differ between
the groups. Notably, although restenosis was frequently
revealed in the side branch in both groups, hardly any
patients underwent TLR. Regarding ST, there was no acute
or subacute ST in the 2 groups. IVUS evaluation after KBT,
and performing additional ballooning when underexpansion
is revealed could also reduce ST in the acute or subacute
phase. However, very late ST was revealed in two patients
in the C group alone. Predictors of ST are said to be AMI,
long stent length [20], bifurcation [21], discontinuation of
antiplatelet drugs, diabetes mellitus, renal failure, low left
ventricular function [22], and stent fracture [23]. In this
study, one patient self-discontinued antiplatelet medica-
tion at 13 months after the procedure, and stent fracture
was revealed in another patient. One patient had an onset
of AMI, and one patient had acute coronary syndrome but
they survived to be discharged from the hospital. Although
stent fracture cannot be predicted, its risks can be reduced
through ways such as using a short stent. In cases where
complex stenting like crush stenting is performed, it could
be possible to lower the incidence of stent thrombosis by
having the patient understand the importance of taking
antiplatelets drugs as directed.Study limitation
This study was limited by its small study population and
by the fact that it was a retrospective study. It has been
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eported that provisional T-stenting is the favorable strat-
gy for true bifurcations [24], but because this current study
ook the policy of performing crush stenting on such lesions,
he C group consequently had a large percentage of true
ifurcations, and moreover, a difference was also seen for
ide branch RD and a difference appeared in the lesion char-
cteristics. Because bifurcation lesions also present issues
uch as late thrombosis, we believe a prospective study with
larger study population is necessary.
onclusions
o differences in chronic clinical outcomes were revealed in
comparison between cross-over single stenting and crush
tenting for non-left main bifurcation lesions. Good clinical
utcomes were achieved by both cross-over single stent-
ng and crush stenting in the treatment of non-left main
ifurcation lesions.
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